Methapyrilene

Identification

Name
Methapyrilene
Accession Number
DB04819
Type
Small Molecule
Groups
Withdrawn
Description

Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.

Structure
Thumb
Synonyms
  • 2-[[2-(Dimethylamino)ethyl]-2-thenylamino]pyridine
  • Methypyrilene
  • N,N-Dimethyl-N'-pyrid-2-yl-N'-2-thenylethylenediamine
  • Thenylpyramine
Product Ingredients
IngredientUNIICASInChI Key
Methapyrilene HydrochlorideNot Available135-23-9BONORRGKLJBGRV-UHFFFAOYSA-N
International/Other Brands
Co-Pyronil / Histadyl / Lullamin
Categories
UNII
00S42N58OM
CAS number
91-80-5
Weight
Average: 297.847
Monoisotopic: 297.106646052
Chemical Formula
C14H20ClN3S
InChI Key
BONORRGKLJBGRV-UHFFFAOYSA-N
InChI
InChI=1S/C14H19N3S.ClH/c1-16(2)9-10-17(12-13-6-5-11-18-13)14-7-3-4-8-15-14;/h3-8,11H,9-10,12H2,1-2H3;1H
IUPAC Name
N-[2-(dimethylamino)ethyl]-N-(thiophen-2-ylmethyl)pyridin-2-amine hydrochloride
SMILES
Cl.CN(C)CCN(CC1=CC=CS1)C1=CC=CC=N1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Methapyrilene H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Methapyrilene.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Methapyrilene.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Methapyrilene.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Methapyrilene.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Methapyrilene.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Methapyrilene.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methapyrilene.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methapyrilene.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Methapyrilene.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methapyrilene.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Methapyrilene.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methapyrilene.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Methapyrilene.Approved
AmperozideThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Amperozide.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Methapyrilene.Approved, Illicit, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methapyrilene.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Methapyrilene.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Azaperone.Investigational, Vet Approved
AzelastineMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Methapyrilene.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Methapyrilene.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Methapyrilene.Approved, Investigational
BenzphetamineBenzphetamine may decrease the sedative activities of Methapyrilene.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineMethapyrilene may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Methapyrilene.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Methapyrilene.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methapyrilene.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Methapyrilene.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methapyrilene.Approved, Investigational
BuprenorphineMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Methapyrilene.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methapyrilene.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Methapyrilene.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Methapyrilene.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methapyrilene.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methapyrilene.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Methapyrilene.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Methapyrilene.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methapyrilene.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Methapyrilene.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Methapyrilene.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methapyrilene.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Methapyrilene.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methapyrilene.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methapyrilene.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Methapyrilene.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methapyrilene.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methapyrilene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Methapyrilene.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methapyrilene.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Methapyrilene.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Methapyrilene.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Methapyrilene.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Methapyrilene is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Methapyrilene.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Methapyrilene.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Methapyrilene.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methapyrilene.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methapyrilene.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Methapyrilene.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methapyrilene.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Methapyrilene.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methapyrilene.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Methapyrilene.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Methapyrilene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methapyrilene.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Methapyrilene.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Methapyrilene.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methapyrilene.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of sedation and somnolence can be increased when Methapyrilene is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methapyrilene.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methapyrilene.Approved, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Methapyrilene.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methapyrilene.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methapyrilene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Methapyrilene.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Methapyrilene.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Methapyrilene.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Methapyrilene.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methapyrilene.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methapyrilene.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methapyrilene.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methapyrilene.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methapyrilene.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methapyrilene.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Methapyrilene.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Methapyrilene is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Methapyrilene.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methapyrilene.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Methapyrilene.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Methapyrilene.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Methapyrilene.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Methapyrilene.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Methapyrilene.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methapyrilene.Approved, Investigational
EthanolMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methapyrilene.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methapyrilene.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Methapyrilene.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Methapyrilene.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methapyrilene.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methapyrilene.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Methapyrilene.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Methapyrilene.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Methapyrilene.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methapyrilene.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methapyrilene.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Methapyrilene.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Methapyrilene.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Methapyrilene.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Methapyrilene.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Methapyrilene.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methapyrilene.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methapyrilene.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methapyrilene.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Methapyrilene.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Methapyrilene.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Methapyrilene.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methapyrilene.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Methapyrilene.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Methapyrilene.Approved, Illicit, Investigational
GepefrineGepefrine may decrease the sedative activities of Methapyrilene.Experimental
GepironeThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Methapyrilene.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Methapyrilene.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Methapyrilene.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methapyrilene.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Methapyrilene.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Methapyrilene.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methapyrilene.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methapyrilene.Approved, Investigational
HydrocodoneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methapyrilene.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Methapyrilene.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methapyrilene.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Methapyrilene.Approved
IndalpineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Methapyrilene.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Methapyrilene.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Methapyrilene.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methapyrilene.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methapyrilene.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Methapyrilene.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Methapyrilene.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Methapyrilene.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Methapyrilene.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methapyrilene.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methapyrilene.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methapyrilene.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Methapyrilene.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Methapyrilene.Approved
LofentanilThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Methapyrilene can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Methapyrilene.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methapyrilene.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methapyrilene.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methapyrilene.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Methapyrilene can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Methapyrilene.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Methapyrilene.Approved
MedazepamThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Methapyrilene.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Melperone.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Methapyrilene.Investigational
MephentermineMephentermine may decrease the sedative activities of Methapyrilene.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methapyrilene.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methapyrilene.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methapyrilene.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Methapyrilene.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methapyrilene.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Methapyrilene.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Methapyrilene.Approved, Illicit
MethaqualoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Methapyrilene.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Methapyrilene.Approved
MethotrimeprazineMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methapyrilene.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Methapyrilene.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Methapyrilene.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Methapyrilene.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methapyrilene.Approved
MetyrosineMethapyrilene may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Methapyrilene.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative activities of Methapyrilene.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Approved, Investigational
MirtazapineMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may decrease the sedative activities of Methapyrilene.Experimental, Illicit
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Methapyrilene.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methapyrilene.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methapyrilene.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methapyrilene.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Methapyrilene.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Methapyrilene.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methapyrilene.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Methapyrilene.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methapyrilene.Approved
OpiumThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Opium.Approved, Illicit
OrphenadrineMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methapyrilene.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methapyrilene.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methapyrilene.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methapyrilene.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methapyrilene.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methapyrilene.Approved
ParaldehydeMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methapyrilene.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methapyrilene.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Approved
PerazineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methapyrilene.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methapyrilene.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methapyrilene.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Phenoxyethanol.Approved
PhenterminePhentermine may decrease the sedative activities of Methapyrilene.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Methapyrilene.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methapyrilene.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Methapyrilene.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Methapyrilene.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Methapyrilene.Approved
PramipexoleMethapyrilene may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Methapyrilene.Approved, Illicit
PregabalinThe therapeutic efficacy of Methapyrilene can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Methapyrilene.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Methapyrilene.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Methapyrilene.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methapyrilene.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Methapyrilene.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Methapyrilene.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methapyrilene.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Methapyrilene.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methapyrilene.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Methapyrilene is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Methapyrilene.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Methapyrilene.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methapyrilene.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Methapyrilene.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methapyrilene.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methapyrilene.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methapyrilene.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methapyrilene.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ritanserin.Investigational
RitobegronRitobegron may decrease the sedative activities of Methapyrilene.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Romifidine.Vet Approved
RopiniroleMethapyrilene may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methapyrilene.Approved
RotigotineMethapyrilene may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methapyrilene.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methapyrilene.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methapyrilene.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methapyrilene.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Methapyrilene.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methapyrilene.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methapyrilene.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Sultopride.Experimental
SuvorexantMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Methapyrilene.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methapyrilene.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Methapyrilene.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tetrodotoxin.Investigational
ThalidomideMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methapyrilene.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Methapyrilene.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methapyrilene.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methapyrilene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Methapyrilene.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methapyrilene.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methapyrilene.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Methapyrilene.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methapyrilene.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methapyrilene.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Methapyrilene.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Methapyrilene.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methapyrilene.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methapyrilene.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Methapyrilene.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Methapyrilene.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Methapyrilene.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Methapyrilene.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methapyrilene.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Methapyrilene.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methapyrilene.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Zolazepam.Vet Approved
ZolpidemMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Methapyrilene.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Methapyrilene.Approved
ZotepineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methapyrilene.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C11114
PubChem Compound
8667
PubChem Substance
46505007
ChemSpider
8345
ChEBI
38213
ChEMBL
CHEMBL1255739
Wikipedia
Methapyrilene
ATC Codes
R06AC05 — Methapyrilene

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
boiling point (°C)173-175 °C at 3.00E+00 mm HgNot Available
water solubility601 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.87SANGSTER (1994)
logS-2.64ADME Research, USCD
pKa8.85 (at 20 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
logP3.11ChemAxon
pKa (Strongest Basic)8.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area19.37 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity78.16 m3·mol-1ChemAxon
Polarizability29.5 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9873
Blood Brain Barrier+0.9492
Caco-2 permeable+0.6224
P-glycoprotein substrateSubstrate0.6832
P-glycoprotein inhibitor INon-inhibitor0.9755
P-glycoprotein inhibitor IINon-inhibitor0.9142
Renal organic cation transporterInhibitor0.5832
CYP450 2C9 substrateNon-substrate0.7548
CYP450 2D6 substrateNon-substrate0.7717
CYP450 3A4 substrateNon-substrate0.5307
CYP450 1A2 substrateInhibitor0.831
CYP450 2C9 inhibitorNon-inhibitor0.8932
CYP450 2D6 inhibitorInhibitor0.8168
CYP450 2C19 inhibitorNon-inhibitor0.7581
CYP450 3A4 inhibitorNon-inhibitor0.9942
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7722
Ames testNon AMES toxic0.888
CarcinogenicityNon-carcinogens0.9043
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5098 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.847
hERG inhibition (predictor II)Non-inhibitor0.6318
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-9321100000-38a0087cd9f89575fa1a

Taxonomy

Description
This compound belongs to the class of organic compounds known as dialkylarylamines. These are aliphatic aromatic amines in which the amino group is linked to two aliphatic chains and one aromatic group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Dialkylarylamines
Alternative Parents
Aminopyridines and derivatives / Imidolactams / Thiophenes / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrochlorides / Hydrocarbon derivatives
Substituents
Dialkylarylamine / Aminopyridine / Imidolactam / Pyridine / Heteroaromatic compound / Thiophene / Tertiary aliphatic amine / Azacycle / Organoheterocyclic compound / Organopnictogen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
hydrochloride (CHEBI:38213)

Drug created on September 11, 2007 14:19 / Updated on June 02, 2018 09:27